D.E. Shaw & Co
RPTX

D.E. Shaw & Co’s Repare Therapeutics RPTX Stock Holding History

D.E. Shaw & Co’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-149,748
Closed -$515K – 4800
2024
Q3 		$515K Buy
149,748
+174
+0.1% +$573 ﹤0.01% 3688
2024
Q2 		$494K Buy
149,574
+29,441
+25% +$105K ﹤0.01% 3631
2024
Q1 		$566K Buy
120,133
+42,954
+56% +$275K ﹤0.01% 3417
2023
Q4 		$563K Buy
+77,179
New +$432K ﹤0.01% 3457
2023
Q3 		– Sell
-11,895
Closed -$126K – 4452
2023
Q2 		$126K Sell
11,895
-31,858
-73% -$328K ﹤0.01% 3809
2023
Q1 		$431K Sell
43,753
-63,521
-59% -$729K ﹤0.01% 3623
2022
Q4 		$1.58M Buy
107,274
+41,890
+64% +$627K ﹤0.01% 3120
2022
Q3 		$793K Sell
65,384
-8,857
-12% -$114K ﹤0.01% 3751
2022
Q2 		$1.04M Buy
+74,241
New +$874K ﹤0.01% 3611

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co's RPTX Position: Q4 2024 in Review

D.E. Shaw & Co sold out of Repare Therapeutics (RPTX) in Q4 2024, closing a stake of 149,748 shares — an estimated $515K sold.

D.E. Shaw & Co first reported a position in RPTX in Q2 2022 and held it in 9 quarters. The position peaked at $1.58M in Q4 2022. 54 funds tracked by Wall St. Rank hold RPTX as of Q4 2024.

  • D.E. Shaw & Co reported no remaining Repare Therapeutics position as of Q4 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 149,748 Repare Therapeutics shares in Q4 2024, an estimated $515K.
  • D.E. Shaw & Co first reported a position in Repare Therapeutics in Q2 2022 and held it in 9 quarters.
  • D.E. Shaw & Co's Repare Therapeutics position peaked at $1.58M in Q4 2022.
  • 54 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2024.

Based on D.E. Shaw & Co's 13F filing for Q4 2024, filed 14 Feb 2025.